US2016230232A1PendingUtilityA1

Fibrosis susceptibility gene and uses thereof

37
Assignee: UNIV AIX MARSEILLEPriority: Feb 19, 2009Filed: Feb 16, 2016Published: Aug 11, 2016
Est. expiryFeb 19, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Alain DesseinViolaine ArnaudChristophe Chevillard
C12Q 1/6883C12Q 2600/118C12Q 2600/156G01N 33/56983C12Q 2600/136C12Q 2600/172Y02A50/30
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses the identification of a fibrosis susceptibility gene locus, the CTGF gene locus, which can be used for detecting predisposition to, diagnosis and prognosis of fibrosis as well as for the screening of therapeutically active drugs. The invention resides, in particular, in a method which comprises detecting in a sample from the subject the presence of an alteration in the CTGF gene locus, the presence of said alteration being indicative of the presence or predisposition to fibrosis.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A method of detecting one or more single nucleotide polymorphism (SNP) in the CTGF gene locus of a human subject, the method comprising:
 (a) obtaining a biological sample from the human subject;   (b) hybridizing a probe to one or more target sequence that comprises the one or more single nucleotide polymorphism (SNP) in the CTGF gene locus; and   (c) detecting the one or more single nucleotide polymorphism (SNP) in the sample,   wherein the one or more target sequence comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and combinations thereof.   
     
     
         16 . The method of  claim 15 , wherein the one or more single nucleotide polymorphism (SNP) is selected from the group consisting of rs12527705 present in a sequence comprising SEQ ID NO: 1, rs12526196 present in a sequence comprising SEQ ID NO: 2, rs9399005 present in a sequence comprising SEQ ID NO: 3, rs6918698 present in a sequence comprising SEQ ID NO: 4, rs3037970 present in a sequence comprising SEQ ID NO: 5, rs1931002 present in a sequence comprising SEQ ID NO: 6, rs2151532 present in a sequence comprising SEQ ID NO: 7, and rs9402373 present in a sequence comprising SEQ ID NO: 8. 
     
     
         17 . The method of  claim 15 , wherein the one or more single nucleotide polymorphism (SNP) is associated with an increased risk of hepatic fibrosis of the human subject. 
     
     
         18 . The method of  claim 17 , wherein the hepatic fibrosis is caused by infection with a virus. 
     
     
         19 . The method of  claim 18 , wherein the virus is hepatitis A virus. 
     
     
         20 . The method of  claim 18 , wherein the virus is hepatitis B virus. 
     
     
         21 . The method of  claim 18 , wherein the virus is hepatitis C virus. 
     
     
         22 . The method of  claim 17 , wherein the hepatic fibrosis is caused by infection with  Schistosoma.    
     
     
         23 . The method of  claim 22 , wherein the  Schistosoma  is  Schistosoma japonicum.    
     
     
         24 . The method of  claim 22 , wherein the  Schistosoma  is  Schistosoma mansoni.    
     
     
         25 . A method of determining an increased risk of hepatic fibrosis in a human subject, the method comprising:
 (a) obtaining a biological sample from the human subject;   (b) hybridizing a probe to one or more target sequence that comprises one or more single nucleotide polymorphism (SNP) of the CTGF gene locus; and   (c) detecting the one or more single nucleotide polymorphism (SNP) in the sample,   wherein the one or more target sequence comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and combinations thereof.   
     
     
         26 . The method of  claim 25 , wherein the one or more single nucleotide polymorphism (SNP) is selected from the group consisting of rs12527705 present in a sequence comprising SEQ ID NO: 1, rs12526196 present in a sequence comprising SEQ ID NO: 2, rs9399005 present in a sequence comprising SEQ ID NO: 3, rs6918698 present in a sequence comprising SEQ ID NO: 4, rs3037970 present in a sequence comprising SEQ ID NO: 5, rs1931002 present in a sequence comprising SEQ ID NO: 6, rs2151532 present in a sequence comprising SEQ ID NO: 7, and rs9402373 present in a sequence comprising SEQ ID NO: 8. 
     
     
         27 . The method of  claim 25 , wherein the hepatic fibrosis is caused by infection with a virus. 
     
     
         28 . The method of  claim 27 , wherein the virus is hepatitis A virus. 
     
     
         29 . The method of  claim 27 , wherein the virus is hepatitis B virus. 
     
     
         30 . The method of  claim 27 , wherein the virus is hepatitis C virus. 
     
     
         31 . The method of  claim 25 , wherein the hepatic fibrosis is caused by infection with  Schistosoma.    
     
     
         32 . The method of  claim 31 , wherein the  Schistosoma  is  Schistosoma japonicum.    
     
     
         33 . The method of  claim 31 , wherein the  Schistosoma  is  Schistosoma mansoni.

Join the waitlist — get patent alerts

Track US2016230232A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.